{"created":"2023-05-15T14:52:11.452696+00:00","id":71268,"links":{},"metadata":{"_buckets":{"deposit":"da0a06e7-7680-4071-bd14-1fbe18136d66"},"_deposit":{"created_by":1,"id":"71268","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"71268"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00071268","sets":["10:28"]},"author_link":["700588","700589","700594","700592","700595","700584","700586","700597","700596","700591","700585","700590","700593","700587"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2013-09-25","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Purpose/Objective(s)\nTo estimate the toxicity and efficacy of carbon ion radiotherapy for adenocarcinoma of the head-and-neck.\nMaterials/Methods\nBetween April 1997 and February 2012, a total of 50 patients with adenocarcinoma of the head-and-neck were treated with carbon ion radiotherapy. None of these patients had either regional lymph node or distant metastasis before radiotherapy.The prescribed tumor doses were 57.6 or 64.0 GyE in 16 fractions over four weeks. All patients provided written informed consent before enrollment in this study.\nThe National Institute of Radiological Sciences Ethical Committee on Human Clinical Research has approved this study.\nResults\nThe patients consisted of 29 males and 21 females aged from 26 to 80 years with an average age of 61 years. As for the tumor sites studied, there were 15 paranasal sinus, 9 orbit, 7 nasal cavity, 7 major salivary gland, 5 pharynx, 4 oral cavity, 2 external ear canal and 1 parapharyngeal space. Forty-one of 50 patients with unresectable tumors or with recurrence and residual tumors after other treatment were permitted to partake in the carbon ion radiotherapy. The gross tumor volume ranged from 1.8 to 227.7 ml, with an average of 67.2 ml.Median follow-up time was 42.5 months (range, 3.9-179.8 months). Although acute grade 3 skin and mucosal reactions appeared in 2 of 50 patients (4%) and 8 of 45 patients (18%), almost all of the late skin and mucosal reactions were grade 1 or less. At the time of analysis, there was no evidence of any unexpected severe toxicity to the critical organs. The 5-year local control and overall survival rates of all patients were 83% and 55%, respectively. As for the T stage studied, the 5-year local control rates were 88% for stage from T1 to T3, 74% for T4 and 88% for recurrence and residual tumors after other treatment. The 5-year overall survival rates were 88% for stage from T1 to T3, 42% for T4 and 54% for recurrence and residual tumors after other treatment, respectively.\nConclusions\nOur results showed acceptable toxicities and excellent therapeutic effectiveness for adenocarcinomas.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"ASTRO's 55th Annual Meeting","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Hasegawa, Azusa"}],"nameIdentifiers":[{"nameIdentifier":"700584","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Koto, Masashi"}],"nameIdentifiers":[{"nameIdentifier":"700585","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Takagi, Ryo"}],"nameIdentifiers":[{"nameIdentifier":"700586","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sasahara, Go"}],"nameIdentifiers":[{"nameIdentifier":"700587","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ikawa, Hiroaki"}],"nameIdentifiers":[{"nameIdentifier":"700588","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Hiroshi"}],"nameIdentifiers":[{"nameIdentifier":"700589","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kamada, Tadashi"}],"nameIdentifiers":[{"nameIdentifier":"700590","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"長谷川 安都佐","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"700591","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"小藤 昌志","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"700592","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"高木 亮","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"700593","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"佐々原 剛","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"700594","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"伊川 裕明","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"700595","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻 比呂志","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"700596","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鎌田 正","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"700597","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Carbon Ion Radiotherapy For Adenocarcinoma of The Head and Neck","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Carbon Ion Radiotherapy For Adenocarcinoma of The Head and Neck"}]},"item_type_id":"10005","owner":"1","path":["28"],"pubdate":{"attribute_name":"公開日","attribute_value":"2013-09-30"},"publish_date":"2013-09-30","publish_status":"0","recid":"71268","relation_version_is_last":true,"title":["Carbon Ion Radiotherapy For Adenocarcinoma of The Head and Neck"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T19:53:13.820490+00:00"}